Renalgan (metamizole sodium, fenpiverinium bromide) solution for injections 5 ml. ampoules №5

Description

Renalgan (metamizole sodium, fenpiverinium bromide) solution for injections 5 ml. ampoules №5

Composition

active ingredients: metamizole sodium, fenpiverinium bromide, pitofenone hydrochloride;

1 ml of the solution contains metamizole sodium 500 mg, fenpiverinium bromide 0.02 mg, pitofenone hydrochloride 2 mg;

excipient: water for injection.

Dosage form

Injection.

Basic physical and chemical properties: transparent liquid of light yellow color with a slightly greenish tinge.

Pharmacological group

Antispasmodics in combination with analgesics.
ATX code A03D A02.

Pharmacological properties

Renalgan solution for injections is a combined drug with analgesic and antispasmodic properties. The composition of the drug includes three active ingredients: non-narcotic analgesic metamizole sodium (analgin), myotropic antispasmodic pitofenone hydrochloride and anticholinergic agent fenpiverinium bromide. Metamizole is a pyralisole derivative. It has an analgesic, antipyretic and weak anti-inflammatory effect. Pitophenone, like papaverine, has a direct myotropic effect on the smooth muscles of the internal organs and causes them to relax. Fenpiverinium, due to anticholinergic action, has an additional antispasmodic effect on smooth muscles.

Indications

Renalgan solution for injections is used for symptomatic therapy of smooth muscle spasms, pain syndrome of various origins (with renal colic, spasms of the urinary tract, stomach and intestines, spastic dysmenorrhea, biliary dyskinesia, biliary colic, angina pectoris, myocardial infarction, migraine-like headache).

It is also used in the period before and after diagnostic tests (in order to eliminate spasm of the examined organs).
If necessary, it can be prescribed to reduce body temperature in case of colds, infectious and inflammatory diseases.

Contraindications

Renalgan solution for injections is not used:

• with intolerance to the components present in the composition of this medication;
• with a significant violation of the functional state of the liver and / or kidneys;
• with agranulocytosis;
• with leukopenia;
• with anemia of any origin;
• with cytostatic or infectious neutropenia;
• with rhinitis, conjunctivitis, bronchospasm in the past, resulting from the use of non-steroidal anti-inflammatory drugs;
• with bronchial asthma;
• with hepatoporphyria;
• with suspicion of acute surgical pathology;
• with intolerance to pyrazolone derivatives (butadion, tribuzon, antipyrine);
• with hereditary hemolytic anemia;
• with glaucoma;
• with tachycardia;
• with kidney diseases (pyelonephritis, glomerulonephritis);
• with collaptoid conditions;
• with prostate hypertrophy;
• with stenosis of the alimentary canal;
• with megacolon;
• children under 15 years old.

Application during pregnancy and lactation

Do not use.

Method of administration and dosage

Renalgan solution is used parenterally.
The duration of treatment is usually 1-3 days.
The solution is administered intravenously / intramuscularly.
In case of acute pain, 2–5 ml are administered by slow intravenous injection. Re-introduction is possible in 6-8 hours. The maximum is 10 ml / day.
It is recommended to heat the ampoule to body temperature before injection.

Overdose

Symptoms: vomiting, sweating, a feeling of dry mouth, impaired accommodation, drowsiness, arterial hypotension, clouding of consciousness, hepatic / renal failure, convulsions.
Treatment: symptomatic therapy is carried out in the required amount.

Side effects:

• With intramuscular administration, pain at the injection site is possible, with intravenous administration, a decrease in blood pressure. Hyperthermic syndrome, hypertensive crisis were rarely observed.
• Disorders from the digestive system: nausea, constipation, pain / burning in the abdomen.
• Disorders from the immune system: an allergic reaction of varying severity (urticaria, Quincke’s edema, conjunctivitis, Stevens-Johnson syndrome, bronchospastic syndrome, Lyell’s syndrome, anaphylactic shock).
• Blood disorders: thrombocytopenia, leukopenia, agranulocytosis.
• Disorders of the urinary system: nephrotoxicity, proteinuria, oliguria, anuria, interstitial nephritis, red urine staining.
• Disorders from the cardiovascular system: AV block, ventricular extrasystole, decreased cardiac output.
• Disorders from the nervous system: drowsiness, sweating, breathing disorders.